Von Willebrand factor

被引:102
|
作者
Ruggeri, ZM [1 ]
机构
[1] Scripps Res Inst, Dept Mol & Expt Med, Roon Res Lab Arteriosclerosis & Thrombosis, Div Expt Hemostasis & Thrombosis, La Jolla, CA 92037 USA
关键词
D O I
10.1097/00062752-200303000-00008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The adhesive protein von Willebrand factor contributes to platelet function by mediating the initiation and progression of thrombus formation at sites of vascular injury. In the last 2 years, there has been considerable progress in explaining the biologic properties of von Willebrand factor. The three-dimensional structure of specific domains has been explained, with the demonstration of distinct conformational changes in the A1 domain caused by single amino acid substitutions associated with enhanced binding to platelets. The structural and functional properties of the interaction between the von Willebrand factor Al domain and glycoprotein lbalpha have also been elucidated in greater detail, bringing researchers closer to understanding how this adhesive bond can oppose the fluid dynamic effects of rapidly flowing blood to initiate thrombus formation and, concurrently, contribute to platelet activation. Because hemodynamic forces greatly influence platelet responses to vascular injury in stenosed and partially occluded arteries, a detailed description of how von Willebrand factor interacts with tissues and platelets may help in the design of more specific therapeutic inhibitors of arterial thrombosis. Moreover, enlightening findings have been obtained on the link between regulation of von Willebrand factor multimer size and microvascular thrombosis. This progress in basic research has provided critical information to define with greater precision the role of von Willebrand factor in vascular biology and pathology. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:142 / 149
页数:8
相关论文
共 50 条
  • [1] von Willebrand disease and von Willebrand factor
    Sadler, Brooke
    Castaman, Giancarlo
    O'Donnell, James S.
    HAEMOPHILIA, 2022, 28 : 11 - 17
  • [2] von Willebrand Factor and von Willebrand Disease
    王兆钺
    血栓与止血学, 2005, (04) : 147 - 149
  • [4] von Willebrand factor
    Ruggeri, ZM
    JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (04): : 559 - 564
  • [5] Von Willebrand factor
    Bhogal, Pervinder
    Jensen, Melanie
    Hart, Dan
    Makalanda, Levansri
    Collins, George B.
    Spooner, Oliver
    Jaffer, Ounali
    CLINICAL MEDICINE, 2020, 20 (06) : E279 - E279
  • [6] von Willebrand factor
    Ruggeri, ZM
    JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11): : S41 - S46
  • [7] Evaluation of von Willebrand factor activity in factor VIII/von Willebrand factor concentrates with the automated von Willebrand factor: activity IL test
    Mori, Filippo
    Rossi, Paola
    Nardini, Ilaria
    Gambelli, Davide
    Farina, Claudio
    BLOOD COAGULATION & FIBRINOLYSIS, 2010, 21 (03) : 221 - 228
  • [8] Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease
    Batlle, Javier
    Fernanda Lopez-Fernandez, Maria
    Loures Fraga, Esther
    Rodriguez Trillo, Angela
    Almudena Perez-Rodriguez, Maria
    BLOOD COAGULATION & FIBRINOLYSIS, 2009, 20 (02) : 89 - 100
  • [9] Von Willebrand factor binding to heparin in von Willebrand disease
    Rastegar-Lari, G
    Legendre, P
    Ajzenberg, N
    Meyer, D
    Baruch, D
    THROMBOSIS AND HAEMOSTASIS, 1999, : 510 - 511
  • [10] Von Willebrand Factor and von Willebrand disease: prerequisite for diagnostic
    Fressinaud, Edith
    HEMATOLOGIE, 2014, 20 : 6 - 13